PRELUDE THERAPEUTICS INC (PRLD) Current Ratio
- Current ratio · latest quarter: Value 4.07×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.07× | Current assets / current liabilities. $154.90M ÷ $38.04M ≈ 4.07× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 154.90M USD | Assets, Current |
| Current obligations | 38.04M USD | Liabilities, Current |
| Cash and equivalents | 26.33M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 125.43M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 2.03M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $154.90M | $38.04M | $26.33M | $125.43M | (m) | (m) | $2.03M | (m) | 4.07× |
| 2026-03-31 | $84.59M | $41.72M | $21.76M | $59.80M | (m) | (m) | $2.07M | (m) | 2.03× |
| 2025-12-31 | $105.69M | $52.99M | $35.26M | $67.96M | (m) | (m) | $3.98M | (m) | 1.99× |
| 2025-09-30 | $58.33M | $18.19M | $47.53M | $7.42M | (m) | (m) | $2.53M | (m) | 3.21× |
| 2025-06-30 | $76.88M | $20.91M | $25.75M | $47.46M | (m) | (m) | $4.96M | (m) | 3.68× |
| 2025-03-31 | $102.40M | $19.79M | $40.27M | $58.80M | (m) | (m) | $5.83M | (m) | 5.18× |
| 2024-12-31 | $135.90M | $25.64M | $12.47M | $121.14M | (m) | (m) | $7.73M | (m) | 5.30× |
| 2024-09-30 | $156.39M | $22.22M | $11.13M | $142.49M | (m) | (m) | $5.92M | (m) | 7.04× |
| 2024-06-30 | $182.71M | $23.34M | $27.83M | $152.02M | (m) | (m) | $6.17M | (m) | 7.83× |
| 2024-03-31 | $205.37M | $17.64M | $24.71M | $177.22M | (m) | (m) | $5.31M | (m) | 11.64× |
| 2023-12-31 | $235.59M | $21.83M | $25.29M | $207.64M | (m) | (m) | $4.58M | (m) | 10.79× |
| 2023-09-30 | $234.92M | $16.89M | $15.90M | $214.61M | (m) | (m) | $5.17M | (m) | 13.91× |
| 2023-06-30 | $260.21M | $15.19M | $26.45M | $228.54M | (m) | (m) | $5.58M | (m) | 17.13× |
| 2023-03-31 | $175.26M | $19.66M | $18.20M | $154.05M | (m) | (m) | $7.08M | (m) | 8.91× |
| 2022-12-31 | $204.38M | $21.70M | $30.61M | $171.12M | (m) | (m) | $6.78M | (m) | 9.42× |
| 2022-09-30 | $226.89M | $21.56M | $52.02M | $172.02M | (m) | (m) | $10.25M | (m) | 10.52× |
| 2022-06-30 | $248.62M | $15.81M | $50.71M | $195.60M | (m) | (m) | $6.27M | (m) | 15.72× |
| 2022-03-31 | $269.97M | $16.07M | $51.63M | $214.56M | (m) | (m) | $7.39M | (m) | 16.80× |
| 2021-12-31 | $295.12M | $19.20M | $31.83M | $259.40M | (m) | (m) | $7.84M | (m) | 15.37× |
| 2021-09-30 | $325.90M | $19.66M | $61.42M | $259.44M | (m) | (m) | $11.06M | (m) | 16.57× |
| 2021-06-30 | $344.57M | $14.68M | $343.12M | (m) | (m) | (m) | $6.84M | (m) | 23.48× |
| 2021-03-31 | $365.02M | $12.42M | $362.99M | (m) | (m) | (m) | $4.84M | (m) | 29.38× |
| 2020-12-31 | $220.81M | $11.38M | $218.31M | (m) | (m) | (m) | $3.92M | (m) | 19.41× |
| 2020-09-30 | $238.06M | $11.36M | $234.79M | (m) | (m) | (m) | $5.07M | (m) | 20.96× |
| 2019-12-31 | $20.22M | $4.83M | $18.88M | (m) | (m) | (m) | $1.97M | (m) | 4.18× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |